Rick Munarriz, The Motley Fool
Tue, May 27, 2025, 8:37 AM 6 min read
In This Article:
-
Hims & Hers Health, FuboTV, and Groupon have all more than doubled in 2025.
-
These companies took very different paths to their stellar year-to-date results.
-
Hims & Hers Health has had to make some major changes to its business in recent months, but it’s still positioned for healthy growth.
-
10 stocks we like better than Hims & Hers Health ›
This year has had its ups and downs on Wall Street, but some investments are rolling. There are 14 stocks with market caps north of $1 billion that have more than doubled so far in 2025 — and some of the names will surprise you.
Hims & Hers Health (NYSE: HIMS), FuboTV (NYSE: FUBO), and Groupon (NASDAQ: GRPN) — yes, that Groupon — are among those 14 stocks that have more than doubled their shareholder money this year. All three have taken entirely different routes to thumping the market this year.
After it posted a whopping 183% gain last year, it wouldn’t have been shocking to see Hims & Hers Health stock take a breather in 2025. The online healthcare platform that got its start by making it easier for people to secure prescriptions for erectile dysfunction drugs and hair growth treatments blew up last year due to the popularity of its compounded GLP-1 injectables for weight loss.
Because Novo Nordisk (NYSE: NVO) was unable to produce Wegovy fast enough to meet surging demand, the Food and Drug Administration put the drug on its official shortage list. That opened up a legal loophole for businesses that operate as compounding pharmacies to produce and sell their own versions of the patented treatment. Hims & Hers cashed in with its own GLP-1 drug, featuring the same active ingredient found in Wegovy and Ozempic — semaglutide. More importantly, it offered that treatment at more aggressive discounts than Novo Nordisk was putting on the name-brand versions.
Hims & Hers Health was doing fine even before it hopped on the GLP-1 bandwagon in spring 2024. Its revenue has risen by at least 65% in each of the last six years. However, the popular new product helped it accelerate its top-line growth in 2024, and it continued to speed up in the first quarter of this year, when revenue more than doubled.
This year began with early gains. Late in 2025, incoming President Donald Trump said he would tap Martin Makary to head the FDA. Makary served on the board of a company that also was into GLP-1 compounding, so the market took the view that Hims & Hers’ upticks would continue even after Novo Nordisk finished ramping up Wegovy production to a level that could meet patient demand. Matters didn’t exactly play out that way.
